Dengue virus type 3 (DENV-3) (DENV-3)

Dengue virus type 3 (DENV-3) is one of the four antigenically distinct serotypes of the Dengue virus, a member of the Flaviviridae family [1]. It is an enveloped, positive-sense single-stranded RNA virus that encodes a polyprotein subsequently cleaved into structural (C, prM, E) and non-structural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) proteins [2]. DENV-3 is a significant human pathogen transmitted by Aedes mosquitoes, causing symptoms ranging from mild fever to severe dengue hemorrhagic fever and shock syndrome [1, 3]. Therapeutic interventions targeting DENV-3 include tetravalent vaccines like Dengvaxia and Qdenga, which aim to elicit protective neutralizing antibodies against the envelope protein [4, 5]. Additionally, small-molecule drug discovery efforts focus on inhibiting essential viral enzymes, particularly the NS5 RNA-dependent RNA polymerase and the NS3 protease [3]. A major challenge in targeting DENV-3 is antibody-dependent enhancement (ADE), where sub-neutralizing antibodies from a previous infection with a different serotype can increase viral uptake and disease severity [3, 5]. Effective management of DENV-3 requires diagnostic monitoring of biomarkers such as the NS1 antigen and viral RNA levels [1].

Other names

Wild-type dengue virus serotype 3Dengue virus serotype 3Dengue virus 3DENV-3

Induction of neutralizing antibodies against viral envelope proteins; inhibition of viral NS5 RNA-dependent RNA polymerase; inhibition of NS3 protease; inhibition of NS4B protein; inhibition of host alpha-glucosidase enzymes.